Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
Go back to Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting| Beam Inc. (NASDAQ: BEAM) | Delayed: 29.03 -0.38 (1.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.41 | 52 Week High | $83.60 | |||
| Open | $29.46 | 52 Week Low | $82.96 | |||
| Day High | $30.50 | P/E | 12.96 | |||
| Day Low | $28.67 | EPS | $2.24 | |||
| Volume | 1,588,226 | |||||
